Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STAA 
STAAR Surgical Company (STAA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: STAA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $24.62
1 Year Target Price $24.62
| 3 | Strong Buy |
| 0 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 33.83% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.36B USD | Price to earnings Ratio - | 1Y Target Price 24.62 |
Price to earnings Ratio - | 1Y Target Price 24.62 | ||
Volume (30-day avg) 14 | Beta 0.62 | 52 Weeks Range 13.50 - 38.60 | Updated Date 08/30/2025 |
52 Weeks Range 13.50 - 38.60 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.56 | Actual -0.34 |
Profitability
Profit Margin -42.45% | Operating Margin (TTM) -55.63% |
Management Effectiveness
Return on Assets (TTM) -10.71% | Return on Equity (TTM) -25.55% |
Valuation
Trailing PE - | Forward PE 625 | Enterprise Value 1206408037 | Price to Sales(TTM) 6.05 |
Enterprise Value 1206408037 | Price to Sales(TTM) 6.05 | ||
Enterprise Value to Revenue 5.38 | Enterprise Value to EBITDA 42.84 | Shares Outstanding 49553000 | Shares Floating 29976117 |
Shares Outstanding 49553000 | Shares Floating 29976117 | ||
Percent Insiders 0.56 | Percent Institutions 110.92 |
Upturn AI SWOT
STAAR Surgical Company
Company Overview
History and Background
STAAR Surgical Company was founded in 1982. Initially focused on surgical products, it evolved to specialize in implantable lenses for refractive vision correction and cataract surgery. Key milestones include FDA approval for its Visian ICL and expansion into international markets.
Core Business Areas
- Implantable Collamer Lenses (ICL): STAAR Surgical's primary business segment, focusing on the design, development, manufacturing, and marketing of ICLs for myopia, hyperopia, and astigmatism correction. These lenses are implanted behind the iris and in front of the natural lens.
- Cataract Lenses: This segment focuses on intraocular lenses (IOLs) used in cataract surgery to replace the natural lens clouded by cataracts.
Leadership and Structure
STAAR Surgical is led by a CEO and executive team, with a board of directors overseeing the company's strategy and operations. The company operates globally with sales and marketing teams in various regions.
Top Products and Market Share
Key Offerings
- Visian ICL: STAAR's flagship product, the Visian ICL, corrects myopia, hyperopia, and astigmatism. Market share is estimated to be growing significantly in the refractive surgery market, with increased adoption among patients seeking alternatives to LASIK. Competitors include Johnson & Johnson Vision, Alcon, and Bausch + Lomb in the broader refractive surgery market.
- Cataract IOLs: STAAR offers a range of IOLs for cataract surgery. This segment is more competitive with established players such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb. Market share information is less granular and varies by region.
Market Dynamics
Industry Overview
The ophthalmic surgical market is driven by an aging population, increasing prevalence of refractive errors, and advancements in surgical technologies. Demand for refractive surgery and cataract surgery is growing globally.
Positioning
STAAR Surgical is positioned as a leader in the refractive surgery market with its Visian ICL technology. Its competitive advantages include the ICL's biocompatibility, reversibility, and ability to correct a wider range of refractive errors compared to LASIK.
Total Addressable Market (TAM)
The TAM for refractive surgery is estimated to be in the billions of dollars globally. STAAR Surgical is capturing an increasing share of this market with its ICL technology and has significant growth potential to increase its market share by focusing on geographic expansion and market penetration.
Upturn SWOT Analysis
Strengths
- Leading ICL technology
- Strong brand reputation
- Growing market share in refractive surgery
- Proprietary Collamer material
- Reversibility of ICL procedure
Weaknesses
- High cost of ICL procedure compared to LASIK
- Reliance on a single product line (ICL)
- Limited geographic presence compared to larger competitors
- Fluctuations of international currency values
- ICL is a surgical procedure and can be intimidating for some patients
Opportunities
- Expanding into new geographic markets
- Increasing awareness of ICL benefits among patients and surgeons
- Developing new applications for ICL technology
- Product Innovation
- Partnering with ophthalmic clinics and surgeons
Threats
- Competition from LASIK and other refractive surgery procedures
- Technological advancements in alternative vision correction methods
- Economic downturns affecting consumer spending on elective procedures
- Regulatory changes
- Pricing pressures from competitors
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- BHC
Competitive Landscape
STAAR Surgical's ICL technology offers advantages in terms of biocompatibility and range of correction. However, it faces competition from larger players with broader product portfolios and established distribution networks.
Growth Trajectory and Initiatives
Historical Growth: STAAR Surgical has experienced strong revenue growth in recent years, driven by increasing adoption of ICL technology.
Future Projections: Analyst estimates project continued revenue growth for STAAR Surgical, driven by geographic expansion and increased market penetration.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts in key markets, developing new ICL designs, and investing in clinical research.
Summary
STAAR Surgical is a strong company specializing in implantable lenses for vision correction, particularly ICLs. Its innovative technology and growing market share position it well for future growth. However, reliance on a single product line and competition from larger players require careful strategic management and focus on geographic expansion and penetration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, market research reports, company website.
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STAAR Surgical Company
Exchange NASDAQ | Headquaters Lake Forest, CA, United States | ||
IPO Launch date 1983-07-15 | CEO & Director Mr. Stephen C. Farrell CFA | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1157 | Website https://www.staar.com |
Full time employees 1157 | Website https://www.staar.com | ||
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.